Jove
Visualize
Contact Us

Related Experiment Videos

Increased plasma antithrombin III level in hyperlipidemic subjects

M P Cucuianu, A Cristea, S Roman

    Clinica Chimica Acta; International Journal of Clinical Chemistry
    |March 5, 1981
    PubMed
    Summary

    Plasma antithrombin III levels are decreased in liver cirrhosis and increased in hyperlipidemia. These levels correlate with cholesterol, triglycerides, and liver function, suggesting altered hepatic protein synthesis in these conditions.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Can Esophageal Anatomy Help to Choose Between Functional Luminal Imaging Probe (FLIP) and Barium Esophagogram in Achalasia?

    Neurogastroenterology and motility·2026
    Same author

    Dual role of HTC products from olive tree prunings in soil: Agricultural amendment or biopesticide depending on phytotoxicity.

    Waste management (New York, N.Y.)·2025
    Same author

    THE GAP BETWEEN GUIDELINES AND PRACTICE: THE NEED TO DE-ESCALATE INTENSITY OF TREATMENT FOR DIFFERENTIATED THYROID CANCER.

    Acta endocrinologica (Bucharest, Romania : 2005)·2025
    Same author

    Physically stable yet biologically sensitive: multiyear ecological dynamics of anoxygenic phototrophs in stably redox-stratified Lake Cadagno.

    Aquatic sciences·2025
    Same author

    The Role of <i>Polycystic Kidney Disease-Like</i> Homologs in Planarian Nervous System Regeneration and Function.

    Integrative organismal biology (Oxford, England)·2024
    Same author

    Whole-Exome Sequencing identified Olfactory Receptor genes as a key contributor to extreme obesity with progression to nonalcoholic steatohepatitis in Mexican patients: Olfactory receptor genes in obese NASH patients.

    Annals of hepatology·2022
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies

    Area of Science:

    • Biochemistry
    • Clinical Chemistry
    • Hepatology

    Background:

    • Plasma antithrombin III is a key regulator of coagulation.
    • Liver disease and dyslipidemia can affect coagulation factor levels.
    • Understanding antithrombin III variations is crucial for managing these conditions.

    Purpose of the Study:

    • To investigate plasma antithrombin III levels in patients with decompensated liver cirrhosis and hyperlipidemia.
    • To explore correlations between antithrombin III and other biochemical markers.

    Main Methods:

    • Measurement of plasma antithrombin III using immunological, clotting, and thrombin-agarose diffusion techniques.
    • Analysis of correlations with serum cholesterol, triglycerides, pseudocholinesterase, and fibrinogen.

    Related Experiment Videos

    Main Results:

    • Plasma antithrombin III was significantly decreased in decompensated liver cirrhosis.
    • Antithrombin III levels were slightly increased in hyperlipidemic and hypertriglyceridemic subjects.
    • Positive correlations were observed between antithrombin III and serum cholesterol, triglyceride levels, and pseudocholinesterase activity.

    Conclusions:

    • Altered hepatic protein synthesis may influence antithrombin III levels in hyperlipoproteinemia.
    • Changes in antithrombin III reflect underlying metabolic disturbances in liver disease and dyslipidemia.